Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 8/20 | 0.55 |
| ▸ | CTSS | P25774 | 7/20 | 0.55 |
| ▸ | CTSB | P07858 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7857680 | 0.90 | CTSL (0.53) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL4455477 | 0.88 | CTSK (0.54) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL7855713 | 0.88 | CTSL (0.53) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL7856620 | 0.87 | LMNA (0.48) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL8373398 | 0.87 | CYP3A4 (0.47) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL7855748 | 0.87 | CYP2C19 (0.53) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL4458161 | 0.87 | CTSL (0.53) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL7856649 | 0.85 | EPHX2 (0.57) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL7859022 | 0.85 | NR1H4 (0.55) | CTSLCTSSCTSBCYP3A4CYP2C19 | |
| SCHEMBL7848771 | 0.85 | CTSL (0.51) | CTSLCTSSCTSBCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | CTSL 972/4885CTSS 783/4885CTSB 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.